ANVISA Mandates Local Leak Testing for Anesthesia Workstations in Brazil

On May 20, 2026, Brazil’s National Health Surveillance Agency (ANVISA) updated Portaria RDC No. 352/2026, Annex III, requiring all anesthesia workstations — including gas mixing, monitoring, and alarm modules — to undergo full-unit gas leakage rate testing at ANVISA-recognized laboratories in Brazil prior to market registration. The regulation also mandates pre-installed standardized physical and digital interfaces to enable direct connection with test equipment. Medical device manufacturers — particularly those based in China supplying to the Brazilian market — must now incorporate these interface provisions during factory production. This development directly affects international exporters, regulatory compliance teams, and supply chain stakeholders serving Latin America’s medical equipment sector.

Event Overview

On May 20, 2026, ANVISA issued an amendment to Portaria RDC No. 352/2026, specifically updating Annex III. The revision requires that anesthesia workstations be tested for gas leakage rate in accordance with ISO 80601-2-13:2022 Annex BB. Testing must be conducted by laboratories accredited by ANVISA and located in Brazil — such as INMETRO-affiliated labs. Additionally, devices must include standardized physical and/or digital interfaces to allow direct connection with test instrumentation. Chinese manufacturers are explicitly required to pre-install these interfaces and provide associated communication protocol documentation before shipment.

Industries Affected

Direct Exporters & OEM Manufacturers

Manufacturers exporting anesthesia workstations from China (and other non-Brazilian jurisdictions) to Brazil will face new pre-market technical and logistical requirements. The need to embed hardware interfaces and deliver protocol documentation adds design, validation, and documentation steps to the product development cycle — potentially delaying registration timelines and increasing certification costs.

Regulatory Affairs & Compliance Service Providers

Firms supporting registration submissions in Brazil must now verify interface implementation and documentation completeness as part of technical file preparation. This introduces a new layer of conformity assessment beyond traditional electrical safety and software verification — extending into hardware-level interoperability with local test infrastructure.

Local Distributors & Authorized Representatives in Brazil

Brazil-based representatives responsible for product registration will need to coordinate early with overseas manufacturers to confirm interface readiness and facilitate lab scheduling. Delays in interface verification may bottleneck the entire submission process, especially given limited capacity at ANVISA-recognized labs.

Supply Chain & Logistics Operators

Logistics providers handling medical device shipments to Brazil may encounter increased scrutiny at customs or during post-market surveillance if interface compliance is not verifiably documented. Non-compliant units risk rejection or mandatory rework — introducing inventory and lead-time risks for distributors.

What Stakeholders Should Focus On — And How to Respond

Monitor official ANVISA guidance on interface specifications

ANVISA has not yet published detailed technical specifications for the required physical/digital interfaces (e.g., connector type, pinout, baud rate, data format). Companies should track updates to RDC No. 352/2026 and related technical notes — especially any forthcoming reference documents or lab implementation guidelines.

Confirm compatibility with INMETRO-accredited laboratories before finalizing designs

Analysis shows that not all ANVISA-recognized labs use identical test setups. Manufacturers should proactively engage with at least one designated Brazilian lab during the design phase to align on interface requirements and avoid late-stage redesigns.

Distinguish between regulatory signal and enforceable requirement

Observably, the regulation takes effect upon publication (May 20, 2026), but enforcement timelines for legacy registrations or transitional arrangements have not been clarified. Stakeholders should treat this as an immediate design consideration for new submissions — while verifying whether existing registered devices fall under grandfathering clauses.

Update internal quality and documentation workflows ahead of first submission

Current more appropriate action is to revise design control procedures, technical file templates, and supplier agreements to include interface verification checkpoints. This includes ensuring firmware versioning, interface labeling, and protocol documentation meet both ISO 13485 and ANVISA’s expectations for traceability.

Editorial Perspective / Industry Observation

This update is better understood as a procedural hardening of ANVISA’s market access framework — rather than a standalone technical shift. From an industry perspective, it reflects a broader trend among emerging-market regulators to strengthen local verification capacity and reduce reliance on foreign test reports. Analysis suggests the interface mandate serves dual purposes: enabling repeatable, lab-controlled testing and creating a technical barrier that favors manufacturers with established regional engineering support. It is not yet clear whether this model will extend to other critical care devices — but its implementation will serve as a benchmark for future ANVISA requirements.

Conclusion: This regulation marks a structural adjustment in how anesthesia workstations gain market access in Brazil — shifting verification responsibility toward local infrastructure and requiring upstream design adaptations. It is not merely a documentation update, but a tangible change in product architecture expectations. Current interpretation should focus on operational readiness: interface integration is now a prerequisite, not an optional feature, for new registrations.

Source: ANVISA Portaria RDC No. 352/2026, Annex III (published May 20, 2026).
Notes for ongoing observation: Specific interface standards, transitional provisions for currently registered devices, and lab capacity timelines remain unconfirmed and require monitoring through ANVISA’s official notices and INMETRO bulletins.